16 result(s) displayed (1 - 16 of 16):
Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth. This Pfizer press release provides a complete list of facilities...
Posted on November 10, 2009 10:45 AM
The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President...
Posted on November 6, 2009 3:50 PM
This afternoon at 2 p.m. EDT, we'll present another in our ongoing series of Webinars on corporate development topics. The topic: effective deal integration in a shifting economy. I'll be moderating, and our panelists will be Timothy Payne, vice president, global acquisitions integration management, LexisNexis Group; Gerald Adolph, senior partner,...
Posted on October 8, 2009 12:10 PM
The approval by Chinese regulators of Pfizer Inc.'s (NYSE:PFE) $68 billion merger with Wyeth (NYSE:WYE) earlier this week offers another glimpse into just how open China will be to foreign investment under its new anti-monopoly law. The conditional clearance -- under which Pfizer will have to divest certain animal health assets in...
Posted on October 1, 2009 3:27 PM
Wyeth's (NYSE:WYE) head of pharmaceutical research Mikael Dolsten has already accepted a job at Pfizer Inc. (NYSE:PFE), which is buying his company for $68 billion, but at an industry conference in San Francisco on Wednesday he barely mentioned his new boss as he touted several drugs in Wyeth's pipeline. In...
Posted on June 17, 2009 2:57 PM
How's this for a sign of the times: One of the most innovative drug industry deals of the year involves the biggest firm of them all, Pfizer Inc. (NYSE:PFE), but it isn't its $68 billion takeover of Wyeth. Instead, the pundits at Windhover Research's In Vivo blog say Pfizer is...
Posted on May 27, 2009 3:00 PM
We're in a deal market with wide gaps between what some buyers are willing to pay and what some sellers think they deserve. In a sector such as pharma-biotech -- one of the few where companies see urgent strategic reasons to get on with dealmaking -- that poses a problem.In...
Posted on May 19, 2009 4:39 PM
First-quarter profits at Johnson & Johnson (NYSE:JNJ) beat analyst estimates thanks partly to the strong performance of Listerine, which J&J got as the prize item in a portfolio of consumer products it bought from Pfizer Inc. (NYSE:PFE) in 2006 for $16.6 billion, nearly 21 times Ebitda.Naturally we noticed, having recently...
Posted on April 14, 2009 2:00 PM
Merck & Co. (NYSE:MRK) is hoping to strengthen its pipeline and broaden its portfolio with its planned $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP). But the megadeal hasn't distracted it from pursuing the kind of smaller licensing deals that have become an increasingly important tool for cost-conscious pharma giants. Merck...
Posted on April 9, 2009 8:03 AM
The latest Corporate Dealmaker column is up on our Deal magazine site. It's a look at the prime consumer brands, including Dr. Scholl's, that may or may not remain a part of the pharma behemoths being formed in the two big deals announced in the first quarter. The deals, of...
Posted on April 1, 2009 12:30 PM
The press release put out by Merck & Co. (NYSE:MRK) on its $41.1 billion deal to acquire Schering-Plough Corp. (NYSE:SGP) puts heavy emphasis on the pharmaceutical pipeline. There's no mention at all of Schering's substantial consumer products business, which sells such brands as Claritin, Coppertone and Dr. Scholl's.Does Merck, with...
Posted on March 9, 2009 10:19 AM
Pfizer Inc. (NYSE:PFE) CEO Jeff Kindler says he admires the decentralized, diversified business models of Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NSYE:ABT), and that he expects Pfizer's pending acquisition of Wyeth to make it more like those companies. He made the remarks in an interview with Bloomberg published Tuesday....
Posted on February 24, 2009 1:01 PM
To those who ask if Pfizer Inc.'s proposed $68 billion acquisition of Wyeth represents the same kind of short-term remedy as the company's past megadeals, CEO Jeff Kindler (pictured) has been giving a consistent answer: We're different now.Kindler expanded on the theme in an interview with The Associated Press that...
Posted on February 9, 2009 10:35 AM
On Monday we were hankering to know more about how the combination of Pfizer Inc. and Wyeth into the most massive pharma company yet would square with the company's press release promise of a "flexible and unique" business model. According to the In Vivo blog (yes, we do link to...
Posted on January 28, 2009 11:40 AM
Industry observers have been saying for years that the blockbuster-driven, marketing-intensive business model for Big Pharma is obsolete, and that the companies who use it have some serious rethinking and restructuring to do. An article by a trio of Bain & Co. consultants, published in 2003, is still relevant. One...
Posted on January 26, 2009 2:28 PM
Pharma industry experts (including ours, for Pipeline subscribers) will be weighing in on this over the course of the day -- and well beyond if the talks about Pfizer Inc. buying Wyeth, reported in The Wall Street Journal and Financial Times this morning, bear fruit.Meanwhile, a few quick thoughts on...
Posted on January 23, 2009 10:08 AM
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
